Inmazeb
Active substance: ATOLTIVIMAB, MAFTIVIMAB, ODESIVIMAB
INJECTION, SOLUTION · ATOLTIVIMAB 483.3 mg/14.5mL, MAFTIVIMAB 483.3 mg/14.5mL, ODESIVIMAB 483.3 mg/14.5mL
United StatesActive
Marketing holder: Regeneron Pharmaceuticals, Inc.
Verified 2026-10-09 · openFDA NDC
- Source: openFDA NDC
- Countries with the substance registered: 1
Composition
- ATOLTIVIMAB · 483.3 mg/14.5mL
- MAFTIVIMAB · 483.3 mg/14.5mL
- ODESIVIMAB · 483.3 mg/14.5mL
Registration
- Registration number
- 61755-019
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- INTRAVENOUS
Sources
- product · openFDA NDC · 61755-019 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 61755-019 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 61755-019 · Verified 2026-10-09 · open in source
- ingredients.1 · openFDA NDC · 61755-019 · Verified 2026-10-09 · open in source
- ingredients.2 · openFDA NDC · 61755-019 · Verified 2026-10-09 · open in source